Comparative Efficacy of IL-17A Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis

IF 1 4区 医学 Q1 DERMATOLOGY Dermatologic Therapy Pub Date : 2026-10-25 DOI:10.1155/dth/9319875
Quan Zhou, Jingyue Ma, Xinzu Tong, Zhimin Wang, Huiping Wang, Powei Wu, Wangyang Zhao, Minghui Jiang, Ruixin Tan, Qintian Zhou, Zhidong Wang
{"title":"Comparative Efficacy of IL-17A Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis","authors":"Quan Zhou,&nbsp;Jingyue Ma,&nbsp;Xinzu Tong,&nbsp;Zhimin Wang,&nbsp;Huiping Wang,&nbsp;Powei Wu,&nbsp;Wangyang Zhao,&nbsp;Minghui Jiang,&nbsp;Ruixin Tan,&nbsp;Qintian Zhou,&nbsp;Zhidong Wang","doi":"10.1155/dth/9319875","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Background</h3>\n \n <p>Interleukin-17A (IL-17A) inhibitors demonstrate strong efficacy among biologic therapies for plaque psoriasis. However, comparative analyses within the IL-17A class, particularly studies including newer agents vunakizumab and xeligekimab, remain scarce.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To compare the efficacy and safety of four IL-17A inhibitors (secukinumab, ixekizumab, vunakizumab, and xeligekimab) for adult patients with moderate-to-severe plaque psoriasis.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A systematic review and network meta-analysis of randomized controlled trials (RCTs) compared four IL-17A inhibitors with placebo. The protocol was registered with PROSPERO (CRD420251266904). Outcomes included PASI 75, 90, and 100 responses at Week 12. Treatments were ranked using the surface under the cumulative ranking curve (SUCRA). Safety outcomes were assessed descriptively.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Seventeen RCTs with 11,044 patients were included. All IL-17A inhibitors significantly outperformed placebo across efficacy endpoints at Week 12. Secukinumab 300 mg consistently ranked 1st for PASI 75 (SUCRA: 96.1%), PASI 90 (SUCRA: 93.8%), and PASI 100 (SUCRA: 95.3%). Vunakizumab 240 mg ranked 3rd for PASI 75 (SUCRA: 77.7%) but improved to 2nd place for PASI 90 (SUCRA: 80.0%) and PASI 100 (SUCRA: 81.9%), though with overlapping credible intervals relative to secukinumab 150 mg at these higher clearance endpoints. Secukinumab 150 mg ranked 2nd for PASI 75 (SUCRA: 82.1%) but 3rd place for PASI 90 (SUCRA: 73.0%) and 4th place for PASI 100 (SUCRA: 63.4%). Safety data were assessed descriptively only; no formal statistical comparison was performed. Observed adverse event rates varied across trials but could not be reliably compared due to differing observation windows and study designs.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Based on this network meta-analysis of Week 12 efficacy, secukinumab 300 mg achieved the highest SUCRA rankings across PASI 75, 90, and 100 endpoints, though credible intervals overlapped with other active treatments and all comparisons were indirect. These rankings are hypothesis-generating and should not be interpreted as evidence of definitive superiority; head-to-head trials are needed to confirm any between-agent differences. Vunakizumab 240 mg and secukinumab 150 mg also showed robust efficacy; however, overlapping credible intervals limit firm distinctions between individual agents. While short-term safety profiles appeared comparable across agents, long-term real-world evidence remains essential to fully characterize the benefit–risk profiles of newer biologics.</p>\n </section>\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2026-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9319875","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/9319875","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Interleukin-17A (IL-17A) inhibitors demonstrate strong efficacy among biologic therapies for plaque psoriasis. However, comparative analyses within the IL-17A class, particularly studies including newer agents vunakizumab and xeligekimab, remain scarce.

Objectives

To compare the efficacy and safety of four IL-17A inhibitors (secukinumab, ixekizumab, vunakizumab, and xeligekimab) for adult patients with moderate-to-severe plaque psoriasis.

Methods

A systematic review and network meta-analysis of randomized controlled trials (RCTs) compared four IL-17A inhibitors with placebo. The protocol was registered with PROSPERO (CRD420251266904). Outcomes included PASI 75, 90, and 100 responses at Week 12. Treatments were ranked using the surface under the cumulative ranking curve (SUCRA). Safety outcomes were assessed descriptively.

Results

Seventeen RCTs with 11,044 patients were included. All IL-17A inhibitors significantly outperformed placebo across efficacy endpoints at Week 12. Secukinumab 300 mg consistently ranked 1st for PASI 75 (SUCRA: 96.1%), PASI 90 (SUCRA: 93.8%), and PASI 100 (SUCRA: 95.3%). Vunakizumab 240 mg ranked 3rd for PASI 75 (SUCRA: 77.7%) but improved to 2nd place for PASI 90 (SUCRA: 80.0%) and PASI 100 (SUCRA: 81.9%), though with overlapping credible intervals relative to secukinumab 150 mg at these higher clearance endpoints. Secukinumab 150 mg ranked 2nd for PASI 75 (SUCRA: 82.1%) but 3rd place for PASI 90 (SUCRA: 73.0%) and 4th place for PASI 100 (SUCRA: 63.4%). Safety data were assessed descriptively only; no formal statistical comparison was performed. Observed adverse event rates varied across trials but could not be reliably compared due to differing observation windows and study designs.

Conclusion

Based on this network meta-analysis of Week 12 efficacy, secukinumab 300 mg achieved the highest SUCRA rankings across PASI 75, 90, and 100 endpoints, though credible intervals overlapped with other active treatments and all comparisons were indirect. These rankings are hypothesis-generating and should not be interpreted as evidence of definitive superiority; head-to-head trials are needed to confirm any between-agent differences. Vunakizumab 240 mg and secukinumab 150 mg also showed robust efficacy; however, overlapping credible intervals limit firm distinctions between individual agents. While short-term safety profiles appeared comparable across agents, long-term real-world evidence remains essential to fully characterize the benefit–risk profiles of newer biologics.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
IL-17A抑制剂治疗中重度斑块性银屑病的比较疗效:网络荟萃分析
白细胞介素- 17a (IL-17A)抑制剂在斑块型银屑病的生物治疗中显示出强大的疗效。然而,IL-17A类药物的比较分析,特别是包括新药vunakizumab和xeligekimab的研究仍然很少。目的比较4种IL-17A抑制剂(secukinumab、ixekizumab、vunakizumab和xeligekimab)治疗成人中重度斑块型银屑病的疗效和安全性。方法随机对照试验(rct)的系统评价和网络荟萃分析比较了四种IL-17A抑制剂与安慰剂。该协议已注册到PROSPERO (CRD420251266904)。结果包括第12周的PASI 75、90和100反应。利用累积排序曲线(SUCRA)下的表面对处理进行排序。对安全性结果进行描述性评估。结果纳入17项随机对照试验,共11044例患者。所有IL-17A抑制剂在第12周的疗效终点均显著优于安慰剂。Secukinumab 300 mg在PASI 75 (SUCRA: 96.1%)、PASI 90 (SUCRA: 93.8%)和PASI 100 (SUCRA: 95.3%)中一直排名第一。Vunakizumab 240 mg在PASI 75 (SUCRA: 77.7%)中排名第三,但在PASI 90 (SUCRA: 80.0%)和PASI 100 (SUCRA: 81.9%)中排名第二,尽管在这些更高的清除率终点上,相对于secukinumab 150 mg有重叠的可信间隔。Secukinumab 150 mg在PASI 75中排名第二(SUCRA: 82.1%),在PASI 90中排名第三(SUCRA: 73.0%),在PASI 100中排名第四(SUCRA: 63.4%)。安全性数据仅进行描述性评估;没有进行正式的统计比较。观察到的不良事件发生率在不同的试验中有所不同,但由于不同的观察窗口和研究设计,无法进行可靠的比较。基于第12周疗效的网络荟萃分析,secukinumab 300 mg在PASI 75、90和100个终点中获得了最高的SUCRA排名,尽管可信区间与其他积极治疗重叠,并且所有比较都是间接的。这些排名是假设产生的,不应被解释为绝对优势的证据;需要进行头对头试验来确认药物之间的任何差异。Vunakizumab 240 mg和secukinumab 150 mg也显示出强大的疗效;然而,重叠可信区间限制了个体代理之间的明确区分。虽然不同药物的短期安全性特征具有可比性,但要充分表征新生物制剂的获益-风险特征,长期真实世界的证据仍然是必不可少的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Dermatologic Therapy
Dermatologic Therapy 医学-皮肤病学
CiteScore
7.00
自引率
8.30%
发文量
711
审稿时长
3 months
期刊介绍: Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.
期刊最新文献
Identifying an Early Improvement Cutoff in Psoriasis Area and Severity Index for Outcome Prediction Across Systemic Treatments Early Intervention With Low-Fluence Q-Switched 1064-nm Nd:YAG Laser is Associated With Improved Clinical Outcomes in Postinflammatory Hyperpigmentation: A Retrospective Cohort Study Tildrakizumab in the Treatment of Palmoplantar Plaque Psoriasis—A Multicenter Real-World Retrospective Study Improved Quality of Life and Sleep in Psoriasis Patients Treated With Guselkumab: The CASSIOPEE Study Mechanisms and Therapeutic Advances in Antihistamine-Refractory Chronic Spontaneous Urticaria
wanfang
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1